Open AccessTenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients
Author(s) -
Danhong Yang,
Yuan-Jun Xie,
Nian-feng Zhao,
Hongying Pan,
Mingwei Li,
Haijun Huang
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i9.2746
Subject(s) - adefovir , lamivudine , medicine , gastroenterology , hepatitis b , hepatitis b virus , chronic hepatitis , combination therapy , virology , virus
To assess the efficacy of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM)-resistant patients with a suboptimal response to LAM plus adefovir (ADV).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom